Enliven Therapeutics, Inc. (NASDAQ: ELVN) AI-Powered Stock Analysis
See how Enliven Therapeutics, Inc. scores across key metrics like financial growth, valuation, and market position on the NASDAQ, using AI-driven evaluation.
ELVN●NASDAQ
HealthcareBiotechnology
$58.82
$0.76(1.31%)
U.S. Market opens in 46h 1m
Enliven Therapeutics, Inc. (NASDAQ: ELVN) AI-Powered Stock Analysis
See how Enliven Therapeutics, Inc. scores across key metrics like financial growth, valuation, and market position on the NASDAQ, using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continuously improving this model to increase accuracy and performance.Read our Full DisclaimerEnliven Therapeutics, Inc. (NASDAQ: ELVN) Stock Overall Grade
Enliven Therapeutics, Inc.'s grade for its NASDAQ listing, based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Enliven Therapeutics, Inc.'s overall NASDAQ stock rating.
Forecast
A+Score
90/100Financial Growth
CScore
40/100Fundamental Growth
CScore
45/100Key Ratios
C+Score
55/100Sector Comparison
B+Score
75/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
98/100Analyst Consensus
B+Score
75/100Enliven Therapeutics, Inc. (NASDAQ: ELVN) AI-Powered Stock Analysis
On the NASDAQ, ELVN demonstrates Good performance with an overall Forecast Score of 90/100 (A+), reflecting high confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (45/100, C) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (98/100, A+), the NASDAQ-listed stock shows competitive strength. Analyst Consensus (75/100, B+) suggests High divergence in outlook.(NASDAQ: ELVN) Component Analysis Explained
Understand the key factors behind each Enliven Therapeutics, Inc. (NASDAQ: ELVN) stock grade, including financials, comparisons, and forecasts.